A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT Number: NCT03568344
Many malaria deaths occur in places where people have poor access to preventive and curative health services. Prompt access to quality health services is critical in the case of severe childhood diseases, among which severe malaria is particularly frequent in endemic areas. In communities where parenteral treatment of severe malaria is not available, the World Health Organization (WHO) recommends administration of a single rectal dose of artesunate (RAS) to children less than 6 years, followed by immediate referral to an appropriate facility where the full package of care for severe malaria can be provided.
Many African countries have already endorsed the use of pre-referral RAS. But treatment guidelines vary widely across these countries and often do not align with the WHO recommendation. With the impending availability of quality-assured rectal artesunate (QA RAS) and countries poised to scale-up this intervention, it is critical to investigate the safe and effective implementation of RAS as part of a continuum of care for severe malaria patients. To ensure that RAS is well targeted, it is equally urgent to learn more about frequency, treatment seeking and risk factors for severe malaria at community level. The CARAMAL project has two major components: the pilot implementation of QA RAS in selected areas of the Democratic Republic of the Congo (DRC), Nigeria and Uganda, and operational research on the introduction of QA RAS into established integrated community case management (iCCM) platforms. The CARAMAL project is funded by Unitaid and coordinated by the Clinton Health Access Initiative, Inc. (CHAI). UNICEF is responsible for QA RAS implementation. Swiss TPH in partnership with the local research organizations Akena Associates Ltd. in Nigeria, Kinshasa School of Public Health in DRC and Makerere University School of Public Health in Uganda carries out the operational research component to generate evidence for the responsible implementation of RAS. Finally, the CARAMAL project will generate a better understanding of severe febrile illness, its management at all levels and key determinants of health outcomes.
Looking for future studies?
Notify Me6 month–59 month
All sexes
Observational
Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
Objective(s):
The overall goal of the CARAMAL project is to contribute to reducing malaria mortality in children globally by improving the community management of suspected severe malaria cases. The project will contribute to this goal by advancing the development of operational guidance to catalyse effective and appropriate scale-up of QA RAS as pre-referral treatment of severe malaria.
Accompanying the pilot roll-out of QA RAS by UNICEF, the CARAMAL project will test whether it is feasible to introduce QA RAS into established integrated community case management (iCCM) platforms with only minimal additional supportive interventions and with minimal unintended consequences such as inappropriate use as artemisinin monotherapy.
Through the research activities described in detail below, the CARAMAL project aims to answer the following research questions:
I. What are the minimal requirements of a community case management system to ensure that RAS is an effective part of the continuum of care from the community to a referral facility (defined as a health care facility equipped for inpatient care of severe malaria)?
II. What are the unintended consequences of scaled implementation, such as adverse drug reactions, unforeseen costs [5], or unforeseen issues in treatment of malaria at all levels of care, and how can they be addressed?
III. Is there any use of RAS beyond the recommended guidelines, including full treatment of severe cases with RAS at community level, and the treatment of uncomplicated malaria with RAS?
IV. Can the introduction of pre-referral QA RAS reduce severe malaria case fatality ratio over time under real-world operational circumstances in three distinct settings?
What are the costs and cost-effectiveness of community and peripheral health facility based RAS?
Study Design:
The CARAMAL project has been designed as a multi-country operational research study implemented in three highly malaria-endemic countries. It will be based on a before-and-after plausibility design aligned with the roll-out of QA RAS through established community-based health care provider systems.
Activity 1: A patient surveillance system (PSS) to assess severe febrile illness/suspected severe malaria incidence, case fatality rate, and related clinical patterns, diagnoses, treatment and treatment outcomes from first contact to the point of recovery or death (baseline and after RAS roll-out) Activity 2: Health care provider surveys (HCPS) to establish the availability and uptake of QA RAS at all levels, and health providers' knowledge, attitudes and practices towards RAS (baseline and after RAS roll-out) Activity 3: Household surveys (HHS) to assess treatment seeking, caretakers' knowledge and attitudes towards RAS, and malaria intervention coverage at community level (baseline and after RAS roll-out) Activity 4: An economic evaluation to assess the costs and incremental cost-effectiveness of implementing RAS at community level compared to the current standard of care Activity 5: Routine monitoring of process indicators along the entire case management chain to continuously assess implementation progress of RAS as contextual information for other outcome indicators
Study Population:
Activity 1, Patient surveillance system:
The PSS will include all children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including Community Health Workers (CHWs) and primary health facilities (HF). All children diagnosed at that level with severe febrile illness / suspected severe malaria will then be enrolled in the PSS and tracked at the referral health facility and at the child's home 28 days after initial diagnosis. In addition, all children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility will be enrolled to evaluate treatment seeking, diagnosis, treatment and disease outcome. These children will be excluded from the case fatality ratio analysis.
Activity 2, Health care provider surveys:
The sampling frame will include all registered providers at all levels operating in the study areas, including public and private providers. A simple random sampling approach stratified by provider level (CHW, primary health facility, etc.) will be used to select providers for the survey.
Activity 3, Household surveys:
Household surveys will include randomly sampled households in the study areas. Households will be selected using a two-stage random sampling approach (village-household) whereas the sampling frames will consist of all villages in the study area and all households in the village, respectively.
In each household, the household heads and parents/caretakers of children < 5 years of age will be eligible to participate.
Measurements and Procedures:
Activity 1, patient surveillance system:
All children with severe febrile illness / suspected severe malaria and enrolled into the patient surveillance system (PSS) by a CHW / primary health facility or at the referral health facility will be followed up at their home by a member of the research team. The primary purpose of this visit is to establish the health status of the child using a structured questionnaire. It will also include a section on the parent's/caretaker's experience and attitude towards the use of RAS. During the home follow-up a finger-prick blood sample will be collected from all of children for:
Activity 2, Health care provider surveys:
Activity 3, Household surveys:
Three survey instruments will be completed with participating household heads and/or household members:
Activity 4, Economic evaluation:
Financial and non-financial economic costs will be collected as part of routine project records over the duration of the study. The evaluation will reflect multiple perspectives including individual (i.e. patient), societal, and health systems-level (i.e. government).
Activity 5, Routine monitoring of process indicators:
Programmatic records of the implementation of QA RAS by UNICEF will be continuously assessed, including:
Number of Participants:
Activity 1, Patient surveillance system:
The minimum sample size of 6,032 cases of severe malaria in children < 5 years over 24 months
Activity 2: Health care provider surveys:
Activity 3: Household surveys 906 household survey responses on treatment-seeking for severe febrile illness will be required per country and individual survey round.
Study Sites:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Signed full consent form from parent / guardian
Health care provider interview:
Household survey:
Exclusion criteria
Health care provider interview:
Household survey:
Time frame: From RAS administration up to 28 days
Patient surveillance system (data collected at referral facility at 28 days visit including verbal autopsy)
Time frame: 28 days after RAS administration
Rapid diagnostic test for malaria
Time frame: Through study completion, an average of 2 years
Data obtained through Household surveys (semi-structured interviewer administered Treatment Seeking Questionnaire)
Time frame: From RAS administration up to 28 days
Patient surveillance system (track patients from first point of contact at CHW or primary health facility until referral health facility)
Time frame: Through study completion, an average of 2 years
Patient surveillance system (patients with severe febrile illness reporting directly to referral health facility)
Time frame: Through study completion, an average of 2 years
Patient surveillance system (data collected at CHW / primary HF)
Time frame: Through study completion, an average of 2 years
Patient surveillance system (data collected at referral facility)
Time frame: From RAS administration up to 28 days
Continuous monitoring of patients medical records (referral facility) for adverse events
Time frame: 28 days after RAS administration
Hemoglobin measurement
Time frame: Through study completion, an average of 2 years
Data obtained through routine monitoring of process indicators along the entire case management chain to continuously assess implementation progress of RAS (Programmatic records)
Time frame: Through study completion, an average of 2 years
Data obtained through routine monitoring of process indicators (Programmatic records) and Health care provider surveys (structured checklist to assess the availability of essential medical supplies (incl. RAS) and equipment, human resource capacity, infrastructure and documentation)
Time frame: Through study completion, an average of 2 years
Data obtained through routine monitoring of process indicators (Programmatic records) and Health care provider surveys (structured checklist to assess the availability of essential medical supplies (incl. RAS) and equipment, human resource capacity, infrastructure and documentation and interviewer administered questionnaires to assess the health worker's demographics, education and training, work experience and supervision, type and utility of any work-related training received, knowledge, attitudes and practices relevant to febrile case management (incl. diagnostic algorithm and (RAS) treatment guidelines) and intermittent preventive treatment in infants and pregnancy (IPTi, IPTp), experiences implementing malaria/febrile case management and prevention guidelines)
Time frame: Through study completion, an average of 2 years
Data obtained through routine monitoring of process indicators (Programmatic records)
Time frame: Through study completion, an average of 2 years
Qualitative data obtained through Health care provider surveys (interviewer administered questionnaires to assess the health worker's demographics, education and training, work experience and supervision, type and utility of any work-related training received, knowledge, attitudes and practices relevant to febrile case management (incl. diagnostic algorithm and (RAS) treatment guidelines) and intermittent preventive treatment in infants and pregnancy (IPTi, IPTp), experiences implementing malaria/febrile case management and prevention guidelines)
Time frame: Through study completion, an average of 2 years
Qualitative data obtained through Household surveys (semi-structured interviewer administered Treatment Seeking Questionnaire including attitude towards RAS use)
Time frame: From RAS administration up to 28 days
Costs extracted from the routine accounting documents of the iCCM projects in the three countries, Health care providers surveys and costs incurred by caretakers during referral (PSS Day 28 assessment)
Time frame: Through study completion, an average of 2 years
Incremental cost-effectiveness of QA RAS introduction over current standard of care for management of severe malaria
Swiss Tropical & Public Health Institute
Other
Community Access to Rectal Artesunate for Malaria (CARAMAL): Observational Research in Nigeria, Uganda and DR Congo
Acronym: CARAMAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT05891236
Infections, Malaria
Baltimore, Maryland, United States
View Trial DetailsNCT07060508
Infections, Malaria
Faladié, Koulikoro, Mali
View Trial DetailsNCT04529434
Diarrhoea;Acute, Infections
Dar Es Salaam, Mtwara, Tanzania
View Trial Details